TEL AVIV, Israel and BETHESDA, Maryland, May 24, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals (CNBX), a US bio-pharma company developing novel cannabis-based, personalized medicine solutions for anti-cancer diagnostics and treatment will hold one-on-one meetings at Canada's biggest cannabis business Conference
Cannabics Pharmaceuticals (CNBX), a US, public bio-pharma company dedicated to developing precision medicine solutions for personalized anti-cancer diagnostics and palliative cannabis-based treatments, announced today that its management members are to attend The Lift & Co. Expo (LCBC), Canada's biggest professional cannabis business conference, to be held this week at MTCC, Toronto, Canada.
Cannabics Pharmaceutical's breakthrough technology is based on non-intrusive diagnostic testing for cancer patients, to be employed for selecting the most appropriate and optimal Cannabinoid-based therapies and medications applied to specific patients based on their molecular/cellular screening analysis results.
Join them in Toronto this week!
The company's CEO, Mr. Eyal Barad, will accept one-on-one meetings.
To schedule meetings and any other inquiry, please contact us at: firstname.lastname@example.org
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX) is a US bio-pharma company dedicated to developing precision medicine personalized anti-cancer diagnostics and cannabis based treatments. It is based on Israeli R&D licensed by the Israeli Ministry of Health for scientific and clinical research. Cannabics novel technology pioneers the assimilation of precision medicine into Cannabinoid-based therapies for cancer patients, utilizing original, patented screening technologies, data management and artificial intelligence (AI).
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 5th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself, and bear our name as its Source.